Phytotherapy in the management of benign prostatic hyperplasia

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

Phytotherapeutic agents have gained widespread usage in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. They are marketed as over-the-counter medications in the United States and by prescription in many European countries. Although numerous mechanisms of action have been postulated, it is uncertain which of these are responsible for their clinical response. The efficacy of these agents has not been conclusively proven. Almost all the studies with these products have not been placebo-controlled, double-blind trials of at least 6 months' duration. Thus, the magnitude of the clinical effect is uncertain. It is impossible to compare the phytotherapeutic agents-either the single or multiple extract products-because manufacturers use different extraction processes. So each agent/product must be studied individually. Until more appropriately conducted trials are undertaken, the efficacy of phytotherapeutic agents will remain unproven.

Original languageEnglish (US)
Pages (from-to)71-76
Number of pages6
JournalUrology
Volume58
Issue number6 SUPPL. 1
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Phytotherapy
Lower Urinary Tract Symptoms
Prostatic Hyperplasia
Prescriptions
Placebos
Therapeutics

ASJC Scopus subject areas

  • Urology

Cite this

Phytotherapy in the management of benign prostatic hyperplasia. / Lowe, Franklin C.

In: Urology, Vol. 58, No. 6 SUPPL. 1, 2001, p. 71-76.

Research output: Contribution to journalArticle

@article{5e308bb74b5b435a976d5164609ccdd3,
title = "Phytotherapy in the management of benign prostatic hyperplasia",
abstract = "Phytotherapeutic agents have gained widespread usage in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. They are marketed as over-the-counter medications in the United States and by prescription in many European countries. Although numerous mechanisms of action have been postulated, it is uncertain which of these are responsible for their clinical response. The efficacy of these agents has not been conclusively proven. Almost all the studies with these products have not been placebo-controlled, double-blind trials of at least 6 months' duration. Thus, the magnitude of the clinical effect is uncertain. It is impossible to compare the phytotherapeutic agents-either the single or multiple extract products-because manufacturers use different extraction processes. So each agent/product must be studied individually. Until more appropriately conducted trials are undertaken, the efficacy of phytotherapeutic agents will remain unproven.",
author = "Lowe, {Franklin C.}",
year = "2001",
doi = "10.1016/S0090-4295(01)01303-6",
language = "English (US)",
volume = "58",
pages = "71--76",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "6 SUPPL. 1",

}

TY - JOUR

T1 - Phytotherapy in the management of benign prostatic hyperplasia

AU - Lowe, Franklin C.

PY - 2001

Y1 - 2001

N2 - Phytotherapeutic agents have gained widespread usage in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. They are marketed as over-the-counter medications in the United States and by prescription in many European countries. Although numerous mechanisms of action have been postulated, it is uncertain which of these are responsible for their clinical response. The efficacy of these agents has not been conclusively proven. Almost all the studies with these products have not been placebo-controlled, double-blind trials of at least 6 months' duration. Thus, the magnitude of the clinical effect is uncertain. It is impossible to compare the phytotherapeutic agents-either the single or multiple extract products-because manufacturers use different extraction processes. So each agent/product must be studied individually. Until more appropriately conducted trials are undertaken, the efficacy of phytotherapeutic agents will remain unproven.

AB - Phytotherapeutic agents have gained widespread usage in the treatment of benign prostatic hyperplasia/lower urinary tract symptoms. They are marketed as over-the-counter medications in the United States and by prescription in many European countries. Although numerous mechanisms of action have been postulated, it is uncertain which of these are responsible for their clinical response. The efficacy of these agents has not been conclusively proven. Almost all the studies with these products have not been placebo-controlled, double-blind trials of at least 6 months' duration. Thus, the magnitude of the clinical effect is uncertain. It is impossible to compare the phytotherapeutic agents-either the single or multiple extract products-because manufacturers use different extraction processes. So each agent/product must be studied individually. Until more appropriately conducted trials are undertaken, the efficacy of phytotherapeutic agents will remain unproven.

UR - http://www.scopus.com/inward/record.url?scp=0035655618&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035655618&partnerID=8YFLogxK

U2 - 10.1016/S0090-4295(01)01303-6

DO - 10.1016/S0090-4295(01)01303-6

M3 - Article

C2 - 11750257

AN - SCOPUS:0035655618

VL - 58

SP - 71

EP - 76

JO - Urology

JF - Urology

SN - 0090-4295

IS - 6 SUPPL. 1

ER -